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In a prospective study o f 660 HIV-positive Malawian 
adults, we diagnosed Pneumocystis jirovecii pneumonia 
(PcP) using clinical features, induced sputum  for immunoflu- 
orescent staining, real-time PCR, and posttreatm ent follow- 
up. PcP incidence was highest in patients with the lowest 
CD4 counts, but PcP is uncommon compared with inci­
dences o f pulm onary tuberculosis and bacterial pneumonia.
The incidence of Pneumocystis jirovecii pneumonia (PcP) in HIV-infected adults in the sub-Saharan 
African region remains uncertain. That PcP is common in 
African children <1 year of age is well documented (1), 
but reported prevalence and incidence rates in adult 
African populations vary widely (2). Many of these reports 
were cross-sectional studies in selected populations from 
tertiary hospitals (3-5), and therefore might contain selec­
tion bias that favors identifying higher rates of PcP.
To our knowledge, no large prospective studies have 
been done by using broncho-alveolar lavage (BAL) in 
combination with immunofluorescent (IF) staining for P. 
jirovecii cysts, the diagnostic procedures of choice. Real­
time PCR performed on sputum samples has high sensitiv­
ity but low specificity for PcP (6,7). The few studies in 
African adults that used PCR assays for Pneumocystis did 
not distinguish subclinical colonization from infection, 
mainly because of limited follow-up after diagnosis (3,4). 
We describe here the incidence of PcP from a large cohort 
study of HIV-infected Malawian adults that used a com­
prehensive diagnostic approach that included induced spu­
tum with IF staining, real-time PCR, and follow-up after 
diagnosis and treatment.
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The Study
HIV-infected adults (>15 years of age), who sought 
treatment at a government health center in the township of 
Ndirande, Blantyre, Malawi, were enrolled in a prospec­
tive, community-based study to determine the incidence of 
infections that were preventable by trimethoprim-sul­
famethoxazole prophylaxis (8). Clinical evaluations were 
performed monthly and at sick visits occurring between 
the scheduled monthly evaluations. CD4 counts were 
determined every 4 months. Standardized diagnostic and 
treatment guidelines and case definitions were used. At the 
time of the study, in Malawi, antiretroviral therapy (ART) 
was rarely used, and trimethoprim-sulfamethoxazole pro­
phylaxis was not recommended.
Cases of suspected PcP were identified by patients’ 
clinical signs and symptoms, chest x-ray results, oxygen 
desaturation exercise test results (9), CD4 count, and fail­
ure to improve with antimicrobial treatment without activ­
ity against P  jirovecii. Patients’ sputum production was 
induced by an ultrasonic nebulizer with hypertonic saline, 
followed by IF staining for P  jirovecii cysts. A case was 
classified as clinical PcP when the IF staining for P. 
jirovecii cysts was positive or the participant had strong 
clinical evidence of PcP and negative IF. Clinical follow- 
up data were collected after the episode of suspected PcP.
After the study, real-time PCR for the P  jirovecii 
dihydropteroate synthase and human RNAase P (control 
DNA) was performed on DNA extracted from the stored 
induced sputum slides (10). Clinicians were not aware of 
the PCR results during the study, and laboratory staff per­
forming the PCR was blinded to clinical information and 
IF results. A final diagnosis of confirmed PcP was made 
for any episode with a positive IF result, positive PCR 
result, or both, unless recovery (defined as resolution of 
respiratory symptoms present at the start of the episode) 
without PcP treatment was observed with a minimum of 4 
weeks of follow-up. If the PCR results were positive but 
the patient recovered without active treatment against PcP, 
the result was interpreted as Pneumocystis colonization. A 
negative PCR result ruled out PcP diagnosis in patients 
who had received PcP treatment on the basis of clinical 
evidence alone.
Incidence rates of respiratory diagnoses per 100 per­
son-years of follow-up were calculated with 95% confi­
dence intervals (CIs) based on Poisson distribution. First 
and subsequent episodes in the same person were counted 
separately, except for PcP, because patients with PcP
1Data from this study were presented in part at the 9th College of 
Medicine Research Dissemination Conference, Blantyre, Malawi,
12 Nov 2005 (abstract DCON/05/44), and the XV International 
AIDS Conference, Bangkok, Thailand, 11-16 Jul 2004 (abstract 
MoPeB3198).
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received secondary prophylaxis and exited the study. The 
CD4 count at the time of the episode or within the previ­
ous 6 months was used for analysis.
We used %2, Mann-Whitney, and Student t tests for 
analysis of age, sex, and CD4 counts among diagnoses, 
respectively, using SPSS version 12 software (SPSS Inc., 
Chicago, IL, USA). The study was approved by the 
Institutional Review Boards of the University of Malawi 
College of Medicine, the University of Maryland, and 
Michigan State University.
Beginning in September 2002, 660 adults were 
enrolled in the study and followed up through August 
2004. Baseline CD4 and World Health Organization stage 
data are shown in Table 1. Mean age was 31.7 years (range 
16-66); 437 (66%) were female. Mean duration of follow 
up was 10.7 months (95% CI 10.4-11.5) per person. 
Eighty-six (13%) participants died, and 37 (6%) were 
withdrawn from the study because they started lifelong 
trimethoprim-sulfamethoxazole prophylaxis. Sixty-three 
participants (9.5%) left the area, 20 (3%) withdrew con­
sent, and 119 (17%) were lost to follow up. A smaller pro­
portion of patients from the lower CD4 strata exited the 
study than from the higher CD4 content group.
Ninety-five episodes of suspected PcP occurred in 75 
persons. Outcomes of these episodes are given in Table 2.
Table 1. Baseline characteristics of study participants at 
enrollment, Malawi, 2002-2004*
Characteristic No. episodes PYO
CD4 (cells/mm3)
0 -99 125 83
100-199 159 145
200-499 271 268
>500 77 75
Missing at enrollment 28 19
HIV clinical s taget
I 267 255
II 191 190
III 160 120
IV 42 25
Total 660 591
*PYO, person-years of observation (based on enrollment characteristics). 
fA s defined by World Health Organization criteria.
A final diagnosis of confirmed PcP was made in 6 
episodes, and 9 episodes of Pneumocystis colonization 
were recorded, with a mean follow up of 26 weeks (range 
4-48 weeks). Table 3 shows the incidence rates of PcP and 
other respiratory conditions in the cohort.
With full diagnostic workup including posttreatment 
follow up as the gold standard for the diagnosis of PcP, the 
sensitivity of PCR alone was 100%, the specificity 88%, 
and the positive predictive value 31%. Among episodes in 
which PcP was suspected, the mean CD4 count in patients
Table 2. Outcomes in 95 episodes of suspected Pneumocystis pneumonia (PcP), Malawi, 2002-2004*
Final d iagnosis! Clinical diagnosis}:
No.
episodes IF PCR Follow-up data
Confirmed PcP PcP 2 Pos Pos -
Confirmed PcP PcP 1 Neg Pos -
Confirmed PcP PcP 1 - - Death after 2 wk of PcP treatment (IS not 
done due to respiratory distress)
Confirmed PcP Bronchiectasis 1 Neg Pos Death 1 wk after IS
Confirmed PcP Tuberculosis 1 Neg Pos Improvement but short follow-up (2 wk)
Pneumocystis colonization/ 
pulmonary KS
Pulmonary KS 3§ Neg Pos Death 23 wk after first IS
Pneumocystis colonization/ 
tuberculosis
Tuberculosis 3 Neg Pos Recovery
Pneumocystis colonization/ 
bacterial pneumonia
Bacterial pneumonia 2 Neg Pos Recovery
Pneumocystis colonization/ 
unspecified respiratory illness
Unspecified 
respiratory illness
2 Neg Pos Recovery
Pneumocystis colonization/ 
other diagnosis
Other diagnosis!! 1 Neg Pos Recovery
Unspecified respiratory illness PcP 3 Neg Neg -
Tuberculosis Tuberculosis 19 Neg Neg -
Bacterial pneumonia Bacterial pneumonia 10 Neg Neg -
Unspecified respiratory illness Unspecified 
respiratory illness
20 Neg Neg -
Unspecified respiratory illness Unspecified 
respiratory illness
1 Neg NA Recovery (18 wk follow-up)
Other diagnoses!! Other diagnoses!! 24 Neg Neg -
Other diagnosis!! Other diagnosis!! 1 Neg NA Recovery (>1 y follow-up)
*IF, immunofluorescence stain; Pos, positive; Neg, negative; IS, induced sputum procedure; KS, Kaposi sarcoma; NA, not available. 
fDiagnosis based on clinical evidence, IF, and PCR from an IS sample, and follow-up after episode.
^Diagnosis based on clinical evidence and IF from an IS sample.
§Three episodes occurring in 1 person.
HAmong other diagnoses were sepsis, bronchitis, emphysema, pulmonary KS, and bronchiectasis.
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Table 3. Incidence of Pneumocystis pneumonia (PcP) and other respiratory illnesses, Malawi, 2002-2004*
All CD4 counts CD4Ci-99/m m 3 CD4 100-199/mm 3
Incidence, % Incidence, % Incidence, %
Diagnosis No. events (95% Cl) No. events (95% Cl) No. events (95% Cl)
Confirmed PcP 6 1.0 (0.3-2.2) 5 5.7 (1.9-13.4) 1 0.6 (0.01-3.8)
Bacterial pneum onia! 102 17.3(14.1-21.0) 35 40.2 (28.0-56.0) 42 28.6 (20.6-38.6)
Pulmonary tuberculosis 51 8.6 (6.4-11.3) 20 23.0(14.0-35.5) 25 17.0(11.0-25.1)
Unspecified respiratory 
illness
127 21.5(17.9-25.6) 46 52.9 (38.7-70.5) 38 25.9(18.3-35.5)
*CI, confidence interval.
fDiagnosis based on new consolidations shown on chest x-ray and response to antimicrobial drugs; includes patients with and without positive blood cultures.
with confirmed PcP cases (42.5 cells/mm3, range 1-103) 
was not significantly lower than in those with 
Pneumocystis colonization (89.1 cells/mm3, range 7-194; 
p = 0.28), but was significantly lower than in those with 
other diagnoses (97.0 cells/mm3, range 1-311; p = 0.03). 
Mean age and sex distribution of confirmed PcP. 
Pneumocystis colonization, and other diagnoses were not 
significantly different. The case-fatality rate of confirmed 
PcP was 50%.
Conclusions
This is the first community-based prospective study of 
PcP in a developing country. We found an incidence of PcP 
in Malawian HIV-infected adults of 1.0/100 person-years, 
similar to the rates observed in studies that used less com­
prehensive diagnostic approaches in South African miners 
(0.5/100 person-years) (11 ) and the placebo arms of trials 
of trimethoprim-sulfamethoxazole prophylaxis in Côte 
d’Ivoire (12,13). The incidence in persons with CD4 
counts <200/mm3 (2.5/100 person-years) was clearly 
lower than in AIDS patients in the United States before the 
introduction of routine trimethoprim-sulfamethoxazole 
prophylaxis and highly active ART (10/100 person-years 
[14]). In the lowest CD4 count range (<100/mm3), PcP was 
common, although the incidence was low compared with 
that of bacterial pneumonia and pulmonary tuberculosis.
We believe it is unlikely that we missed many PcP 
cases among other diagnoses or losses to follow-up because 
of the intensive active and passive follow-up and because 
our facility provided expeditious, high-quality care free of 
charge. Allowing for reduced sensitivity of induced sputum 
compared to BAL (7) and considering cases with diagnos­
tic uncertainty as PcP cases would still leave the PcP inci­
dence low in the HIV-infected population in general.
We found that Pneumocystis colonization and con­
firmed PcP were equally common among patients with 
suspected PcP. More sensitive molecular detection meth­
ods would possibly have detected higher rates of coloniza­
tion. It remains uncertain why certain HIV-infected 
persons clear Pneumocystis colonization while others 
develop PcP. The level of immune suppression as indicat­
ed by the CD4 count is a possible explanation, although 
our data do not support this. Genetic differences between
P. jirovecii strains may be relevant (15). Variation in 
worldwide distribution of strains, as well as differences in 
host genetics and shorter survival of patients in low CD4 
count ranges, are possible causes of the lower PcP inci­
dence in Africa than in developed countries.
The incidence of PcP in HIV-infected Malawian 
adults, diagnosed clinically and confirmed with molecular 
analysis, was low compared with the incidence of bacteri­
al pneumonia and pulmonary tuberculosis at all levels of 
immunosuppression. PcP rarely occurred with CD4 cell 
counts >100 mm3. Among the most immunocompromised 
patients, PcP is an important diagnostic consideration.
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